Redeye comments on Annexin’s Q3 report and recent events. The company is about to start a clinical phase IIa study in patients with diabetic retinopathy (DR) and retinal vein occlusion (RVO) - two severe eye diseases with significant market opportunities. The study has been slow-started, but the company is taking steps to ramp up recruitment. We adjust our financial assumptions, resulting in a slightly revised valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/